Site Search
Professionals 49 results
Capabilities 32 results
Practice Area
Derivatives & Structured Products
Winston represents swap dealers, major swap participants, financial intermediaries, hedge funds, national exchanges, and end-users in a broad array of derivative transactions ranging from highly structured transactions to more traditional trading or hedging transactions, and in regulatory and enforcement issues related to commodities and derivatives.
Practice Area
Our structured finance group is widely recognized as a leader, encompassing Esoteric Finance, Residential Asset Finance and Securitization, and CLOs/Fund Finance. Positioned prominently at the forefront of the industry, our team boasts extensive experience across a broad spectrum of assets, with a particular focus on bespoke structures and emerging and/or “esoteric” assets, including residential and commercial PACE, RMBS, and CMBS; aircraft, vessel, and railcar finance; FinTech and marketplace lending; CLOs; specialty finance; consumer and business lending; energy structured finance (including solar finance and reserve-based finance); derivatives and structured products; lease and operating asset finance; trade receivables; litigation settlement financing; and life settlements.
Practice Area
Securities, M&A & Corporate Governance Litigation
In today’s market, litigators with experience in securities, corporate governance, and M&A-related (collectively, “securities litigation”) matters need to leverage their broad experience to serve as both advocate and as counsel and strategist, focused on helping clients to overcome not just a legal issue but a collective business problem. Given the frequent interplay between things such as corporate-control transactions, public offerings, activist shareholders, the use of complex derivatives and other financial instruments, bad news impacting stock performance, regulatory inquiries and investigations, and insurance coverage, strategic and tactical litigation decisions can have a wide-ranging impact on the success of a given transaction, as well as on companies, their boards, senior management, and advisors.
Experience 5 results
Experience
|January 9, 2025
Delaware Court Sees Though Plaintiffs’ Poorly Disguised Derivative Claims
Experience
|September 20, 2021
Socieded Química y Minera de Chile S.A. US$700M 3.500% Notes due 2051 ("Green" Bond Offering)
Winston & Strawn LLP represented Socieded Química y Minera de Chile S.A. (SQM) in connection with its first "green" bond offering of US$700M principal amount of 3.500% Notes due 2051 (the “Green Bonds”). The Green Bonds were sold in an offering exempt from registration pursuant to Rule 144A and Regulation S. The proceeds of the Green Bonds will be used to finance or refinance recently completed or future eligible green projects with respect to lithium production capacity expansion for applications related to clean transportation and energy efficiency. Disbursements may cover project expenditures for up to 36 months preceding the issuance of the Green Bonds and until their maturity date. BofA Securities, Inc.; Goldman Sachs & Co. LLC; J.P. Morgan Securities; and Santander Investment Securities Inc. acted as initial purchasers of the Green Bonds. SQM is a Chile-based global leader in the production of specialty plant nutrients, iodine and derivatives, lithium and derivatives, potassium, and certain industrial chemicals.
Insights & News 224 results
Client Alert
|May 23, 2025
|10+ Min Read
One Big Beautiful Bill: Proposed Tax Changes Clear House and Proceed to Senate
On Thursday, May 22, 2025, Republicans in the House of Representatives passed the One Big Beautiful Bill Act (the Act), advancing proposed changes to the tax law that could significantly impact individuals and businesses. The Act extends several flagship provisions of the 2017 Tax Cuts and Jobs Act (TCJA) and reflects certain campaign promises made by President Trump. In doing so, the Act raises excise taxes on certain tax-exempt organizations, eliminates many of the clean energy tax credits first introduced by the 2022 Inflation Reduction Act, and provides for a $4 trillion increase on the national debt limit.[1] Despite prior indications to the contrary, the Act does not address the treatment of carried interest. The Congressional Budget Office estimates that the cumulative effect of the Act’s changes to the tax law will result in an increase to the federal deficit of approximately $3.8 trillion. The Act now heads to the Senate for consideration.
Capital Markets & Securities Law Watch
|May 20, 2025
|3 Min Read
Texas Governor Signs Law to Raise the Bar for Shareholder Proposals
The Texas Governor signed a bill that raises the bar for shareholder proposals for Texas corporations. The new law, signed by Governor Abbott on May 19, 2025, has major implications for shareholders of certain Texas corporations and is part of a larger effort to make Texas more business-friendly.
Recognitions
|May 14, 2025
|1 Min Read
Winston & Strawn has been recognized as the second most popular international law firm in the Latin America Corporate Counsel Association’s (LACCA) 2024 survey, “Who Represents Latin America’s Biggest Banks?”
Other Results 21 results
Law Glossary
What Is the Patent Trial and Appeal Board?
The Patent Trial and Appeal Board (PTAB) is a tribunal within U.S. Patent and Trademark Office. The PTAB oversees trial proceedings, namely: inter partes review (IPR), post-grant review (PGR), covered business method (CBM) review, and derivation proceedings. The Board also hears appeals from adverse patentability decisions by patent examiners in original applications, reissues, and reexaminations. And, while phasing out since the passage of the America Invents Act (AIA) in 2011, the PTAB is also responsible for deciding interferences. The PTAB was previously referred to as the Board of Patent Appeals and Interferences and was renamed by the AIA.
Law Glossary
A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)
Site Content
The full name of the Dodd-Frank Act is the Dodd-Frank Wall Street Reform and Consumer Protection Act. It was passed in 2010 to regulate the financial market and protect consumers from risky financial practices. The legislation and its rules cover the following: